UK market access · For Indian manufacturers

MHRA Compliance for Indian Pharma Exporters to the UK

A practical roadmap for Indian manufacturers who want to supply the United Kingdom — how MHRA GMP, marketing authorisation, the Responsible Person (import), and UK batch-release rules actually work for a plant based in India, and what to prepare before your first shipment.

Book an Export Consultation → Discuss on WhatsApp or see the UK export roadmap ↓

REVIEWED: July 2026 BASIS: Orange Guide 2022 · Human Medicines Regs 2012

UK Pharma Import Route

MA + WDA(H)

MHRA GMP Inspections 24/25

353 globally

Top MHRA Finding

Data Integrity ~40%

Time To Export-Ready

18–24 months typical

The opportunity, and the gatekeeper

Why the UK is a serious market for Indian manufacturers — and who controls the door

India already supplies roughly a quarter of the UK’s generic medicines, and the India–UK free trade agreement adds regulatory-cooperation measures intended to smooth market access for Indian manufacturers. But the door to the UK is controlled by one body: the Medicines and Healthcare products Regulatory Agency (MHRA).

Since Brexit, the UK operates its own medicines framework under the Human Medicines Regulations 2012, using a modified version of EU GMP captured in the MHRA “Orange Guide.” For an Indian exporter this is the key point: the UK is now a distinct regulated market with its own rules, not a sub-set of the EU. A product cleared for Europe is not automatically cleared for Britain, and the compliance steps are specific.

The MHRA is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and applies PIC/S GMP alongside the Orange Guide, which means an Indian plant already built to WHO-GMP or EU-GMP has a substantial head start — the quality expectations are aligned, even though the UK paperwork route is its own. If your unit is being built or upgraded to Revised Schedule M, our Revised Schedule M compliance dashboard covers the Indian baseline that this UK route builds on.

New for Indian sites: the MHRA has launched a pilot Single Inspection Program with Health Canada and Australia’s TGA — a shared approach to GMP inspection of third-country manufacturers. For an Indian plant, one well-run inspection can increasingly serve several regulated markets at once, which changes the economics of building export-grade.

Choose your route first

What are the routes for an Indian manufacturer to supply the UK?

There is no single “export licence.” The route depends on what you make and how it reaches the UK patient. Getting this decision right first saves months, because it determines every document you will need.

Route 1 — Finished formulations under a UK Marketing Authorisation

To sell a finished medicine in Britain, that product needs a UK Marketing Authorisation (MA) held by a UK-based entity. As the Indian manufacturer, you are named on the MA as the site of manufacture, and your plant must satisfy MHRA GMP expectations — verified either through an MHRA inspection of your site or through recognised GMP evidence. The product then enters the UK via an importer holding a Wholesale Distribution Authorisation, WDA(H). This is the mainstream route for tablets, capsules and liquids destined for UK pharmacies.

Route 2 — Active pharmaceutical ingredients (APIs) to UK formulators

If you supply bulk APIs rather than finished dose, you are selling into UK or EU formulation companies. Here the critical assets are a robust Drug Master File (DMF), and where relevant a Certificate of Suitability (CEP) from the EDQM, which UK and EU formulators can reference directly in their own submissions. API exporters register their activity, and the buyer’s regulatory team will scrutinise your GMP status before a single kilogram is ordered. A focused API plant serving two or three molecules is one of the most capital-efficient India–UK export models.

Route 3 — Contract manufacturing for UK brand owners

A UK company owns the brand and MA; you manufacture to their specification. Commercially this resembles third-party manufacturing, but the quality bar is the UK brand owner’s MA and MHRA expectations rather than the Indian domestic standard. The brand owner’s Qualified Person carries batch-certification accountability, while your obligation is a manufacturing process and documentation set that survives their audit and an MHRA inspection.

Decision rule: finished-dose exporters live or die on the Marketing Authorisation and site GMP; API exporters live or die on the DMF/CEP and buyer audits; contract manufacturers live or die on surviving the brand owner’s QP audit. Identify which one you are before spending on anything else.

Standard comparison

MHRA vs USFDA vs EU-GMP vs WHO-GMP — what changes for an Indian plant?

Most Indian exporters already hold WHO-GMP and are chasing one or more stringent markets. This is how the UK route compares with the others you are likely weighing, so you can decide where the incremental effort goes.

Dimension

UK — MHRA

US — USFDA

EU-GMP / WHO-GMP

GMP basis

Orange Guide + PIC/S PE 009

21 CFR 210/211, cGMP

EU GMP Parts I/II · WHO TRS

Market entry document

UK Marketing Authorisation

ANDA / NDA

EU MA / national MA · CoPP for WHO route

Site verification

MHRA inspection or recognised GMP evidence

Pre-approval & routine FDA inspection

EU/national inspection · WHO-GMP by state/CDSCO

Batch release into market

QP certification; RPi verifies imports

US agent + FDA-compliant release

EU QP certification per batch

Relative build cost for Indian plant

Close to EU-GMP

Highest — equipment cost multiplies

WHO lowest · EU high

Best for

Britain-specific supply, FTA advantage

US generics at scale

Broad export / tenders

If you have not yet costed the plant itself, our pharma plant setup cost calculator prices the same configuration across Revised Schedule M, WHO-GMP, EU-GMP and USFDA, so you can see the capital gap before committing to a UK-grade build. For the US pathway specifically, see our USFDA approval roadmap for Indian formulation plants.

The UK-specific mechanism most exporters miss

What is the Responsible Person (import), and why does it matter to you?

This is the single most common blind spot for exporters new to the UK. The Responsible Person (import), or RPi, is a role unique to Great Britain, created after Brexit. It is worth understanding even though it sits on the UK importer’s side, because it shapes what your documentation must prove.

When a UK wholesale dealer imports a medicine, the RPi is the named person who confirms the batch was properly certified before it entered the UK supply chain. The RPi must be on an MHRA register, hold specific qualifications and professional-body membership, and remain personally accountable even when duties are delegated. For your Indian consignment, this means the importer’s RPi will demand clean, traceable evidence of batch testing and certification — so your batch documentation is not merely an internal record, it is the thing that lets the product legally clear into Britain.

What this means for your batch paperwork

Certificate of Analysis against the registered specification, unambiguous and signed
Batch manufacturing and packaging records that survive scrutiny, with contemporaneous entries
Certificate of Pharmaceutical Product (CoPP) from CDSCO or the state authority, in WHO format, for the product
Traceability from raw-material lot through to finished pack, reconciled and recall-ready
A written quality/technical agreement with your UK importer defining who does what

The practical failure mode: Indian exporters whose domestic documentation is “good enough for CDSCO” but not built to withstand a UK RPi’s verification and an MHRA-style audit. The fix is to raise your batch-record and data-integrity discipline before the first UK order, not after a rejected consignment. This is where a QA-led gap assessment pays for itself many times over.

Where inspections are won and lost

What does MHRA look for in a manufacturing site?

MHRA regulation is principles-based and risk-managed, not a tick-box checklist. Inspectors want evidence that you genuinely control your process — not merely that a procedure exists on paper. Published MHRA findings cluster into a predictable set of failures, and an Indian exporter who closes these before inspection is most of the way to a clean outcome.

Deficiency area

What inspectors actually check

Data integrity
~40% of major findings

Individual (not shared) logins, complete audit trails, inability to quietly delete or overwrite raw analytical data, ALCOA+ discipline across paper and electronic records

Quality system (Chapter 1)
~25% of findings

A real Pharmaceutical Quality System with quality risk management applied to change control, deviations and supplier decisions — plus documented self-inspection and management review

CAPA effectiveness

The full chain from deviation to root cause to action to verified effectiveness — recurring deviations on the same issue signal a weak system

Validation & qualification

Process validation with adequate batches and process knowledge, computerised system validation per GAMP 5, complete equipment DQ/IQ/OQ/PQ per Annex 15

Supplier qualification

Evidence of audits for critical suppliers, quality agreements defining responsibility, risk-based re-audit intervals — a frequent gap for exporters relying on CoA alone

Sterile (Annex 1)

For injectables: contamination control strategy, ISO 14644 classification, media fills, environmental monitoring history over 12+ months, and container closure integrity

For a deeper treatment of the data-integrity standard that dominates these findings, see our guide to ALCOA+ principles. The discipline MHRA rewards is the same one Revised Schedule M now demands domestically — which is why an export ambition and a Schedule M upgrade are best planned as one project, not two.

Step by step

The UK export roadmap for an Indian manufacturer

A realistic sequence from decision to first compliant shipment. Most well-run Indian units reach export readiness in 18–24 months, faster if the plant already holds EU-GMP.

STEP — 01

Fix the route & the product

Decide finished dose, API, or contract manufacture, and the specific molecules. Everything downstream depends on this. Register with Pharmexcil and obtain your IEC from DGFT.

STEP — 02

Close the GMP gap to UK expectations

Commission a documented gap assessment against Orange Guide / PIC/S expectations. Prioritise data integrity, the quality system, and validation — the three areas that dominate MHRA findings.

STEP — 03

Build the dossier & documentation

Assemble the product dossier, DMF/CEP for APIs, stability data to ICH conditions, and batch documentation designed to satisfy a UK RPi and an MHRA auditor — not just CDSCO.

STEP — 04

Secure the UK partner & MA

Line up a UK MA holder / importer with a WDA(H) and a named RPi, or a brand owner for contract manufacture. Put the quality/technical agreement in writing before production.

STEP — 05

Pass the inspection

Prepare for an MHRA GMP inspection of your site — or leverage the Single Inspection Program where eligible. A clean CAPA response to any findings is part of the pass, not an afterthought.

STEP — 06

Ship, release & sustain

First consignment moves under the importer’s release process with your CoPP and batch evidence. Then sustain it: audit readiness is continuous, and one lapse can cost the market.

The FTA tailwind: the India–UK free trade agreement includes regulatory-cooperation provisions intended to ease MHRA approvals for Indian manufacturers who already hold recognised GMP. Building to WHO-GMP or EU-GMP now positions you to use that advantage as it matures, rather than starting from zero later.

Common questions

MHRA compliance for Indian exporters, answered

Does an Indian manufacturer need MHRA approval to export medicines to the UK?

To supply a finished medicine to the UK market, the product needs a UK Marketing Authorisation and your site must satisfy MHRA GMP expectations — verified through an MHRA inspection or recognised GMP evidence. For bulk APIs, you do not need a product MA, but the UK or EU formulator buying from you will require a robust Drug Master File and will verify your GMP status. In every case the UK operates its own rules post-Brexit, so EU clearance does not automatically grant UK access.

What is the difference between MHRA and EU-GMP for an Indian plant?

The quality expectations are closely aligned — the UK’s Orange Guide is a modified version of EU GMP, and both the MHRA and EU apply PIC/S standards. The differences are in market-access paperwork: the UK requires its own Marketing Authorisation, its own batch-import verification through the Responsible Person (import), and, where required, an MHRA inspection of your site. A plant built to EU-GMP has done most of the technical work already; what remains is the UK-specific documentation and partner setup.

What is a Responsible Person (import) and do I need one in India?

The RPi is a UK role, held by your UK importer, not by you. It is the named person who confirms that a batch was properly certified before it entered the UK. You do not appoint an RPi in India, but you must supply the clean, traceable batch documentation — Certificate of Analysis, batch records, CoPP and full traceability — that allows the importer’s RPi to do their job. Weak batch documentation is a common reason Indian consignments stall at UK entry.

Will MHRA inspect my factory in India?

It can. For finished-dose products supplied under a UK Marketing Authorisation, MHRA may inspect your site, or accept recognised GMP evidence depending on the route and risk. The MHRA also runs a pilot Single Inspection Program with Health Canada and Australia’s TGA for third-country manufacturers, which can allow one inspection to serve several markets. Preparing your site to inspection standard — especially on data integrity and the quality system — is essential either way.

Is WHO-GMP enough to export to the UK?

WHO-GMP is a strong foundation and puts you on aligned quality principles, but on its own it does not grant UK market access for finished medicines. You still need the UK Marketing Authorisation route, UK-standard batch documentation, and to satisfy MHRA site expectations. WHO-GMP is best viewed as the platform you build the UK-specific steps on top of, not the finish line.

How long does it take to become UK export-ready?

For a well-run Indian unit, typically 18–24 months from decision to first compliant shipment — faster if the plant already holds EU-GMP, slower if significant gap-closure on data integrity, validation or the quality system is needed. The timeline is driven less by paperwork than by how quickly you can raise site discipline to withstand a UK RPi’s verification and an MHRA-style audit.

Does the India–UK trade agreement make MHRA approval easier?

The India–UK free trade agreement includes regulatory-cooperation provisions intended to facilitate MHRA approvals for Indian manufacturers who already hold recognised GMP certification. It does not remove the need for a Marketing Authorisation or GMP compliance, but it signals a direction that rewards manufacturers who build to WHO-GMP or EU-GMP standards now, positioning them to benefit as cooperation mechanisms mature.

23+ years in pharmaceutical QA, QC & regulatory affairs

Planning to export to the UK? Close the MHRA gap before your first order.

Route selection, GMP gap assessment against UK expectations, dossier and batch-documentation review, and the licensing pathway — from people who have sat on both sides of an inspection.

Book an Export Readiness Consultation → Contact the Team WhatsApp Your Query

DISCLAIMER: This guide is prepared for general information for Indian manufacturers considering UK export and reflects MHRA guidance current at the July 2026 review date (Orange Guide 2022 edition, Human Medicines Regulations 2012, PIC/S PE 009). It is not legal or regulatory advice, and it does not replace the official MHRA Orange Guide, the relevant Annexes, or engagement of a qualified regulatory professional. UK requirements and India–UK trade arrangements continue to evolve; always verify against current MHRA and GOV.UK sources before making compliance or investment decisions.